COMPANY RESEARCHIonis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is a United States company focused on medicines that target RNA to address serious diseases. Its research and marketed medicines draw on oligonucleotide technologies, including antisense approaches that can change production or processing of disease related proteins. Its therapeutic areas include neurological and cardiometabolic conditions, alongside selected rare diseases. Founded in 1989, Ionis is headquartered in Carlsbad, California, and has conducted public trading under the Nasdaq ticker IONS. Several medicines are developed independently and through partnerships.
Company at a glance
Corporate information
- Company entity
- Ionis Pharmaceuticals
- Headquarters / principal office
- Carlsbad, California, United States
Sources (1)
- Ionis investor FAQsAccessed 2026-11-04; undated unless stated
- Founded
- 1989
Sources (1)
- Ionis investor FAQsAccessed 2026-11-04; undated unless stated
- Ownership / capital status
- Publicly tradedPublicly traded (NASDAQ: IONS; IPO in 1991)
Sources (1)
- Ionis investor FAQsAccessed 2026-11-04; undated unless stated
- Official corporate reference
- https://ionis.com/
Sources (1)
- Ionis Pharmaceuticals — official website2026-11-04 retrieval
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Innovating to Change the Course of Human Health | IONISAccessed 2026-11-04; undated unless stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Ionis Pharmaceuticals is a United States company focused on medicines that target RNA to address serious diseases. Its research and marketed medicines draw on oligonucleotide technologies, including antisense approaches that can change production or processing of disease related proteins. Its therapeutic areas include neurological and cardiometabolic conditions, alongside selected rare diseases. Founded in 1989, Ionis is headquartered in Carlsbad, California, and has conducted public trading under the Nasdaq ticker IONS. Several medicines are developed independently and through partnerships.
Nasdaq: IONS
antisense oligonucleotides · RNA-targeted medicines
neurology · cardiometabolic · rare diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Ionis describes a portfolio of RNA- and DNA-targeted medicines, with separate pipeline, medicines, clinical-trial, and scientific-publication resources. Product-specific mechanisms and development status should be checked against dated disclosures.
Business, technology & evidence
- Ionis Pharmaceuticals is a United States company focused on medicines that target RNA to address serious diseases. Its research and marketed medicines draw on oligonucleotide technologies, including antisense approaches that can change production or processing of disease related proteins. Its therapeutic areas include neurological and cardiometabolic conditions, alongside selected rare diseases. Founded in 1989, Ionis is headquartered in Carlsbad, California, and has conducted public trading under the Nasdaq ticker IONS. Several medicines are developed independently and through partnerships.
- SecuritiesNasdaq: IONS
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| ION717 | PRNP · Prion disease | I/IIa期；公司资料 | Human/approved evidence; see original source for scope |
| obudanersen / ION582 | UBE3A-ATS · Angelman syndrome | Phase 3REVEAL；公司资料 | Human/approved evidence; see original source for scope |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Two representative programs added; not a complete pipeline. Later developments, registry status and other indications remain to be checked.
- Ionis Pharmaceuticals — official website ↗Ionis Pharmaceuticals · 2026-11-04 retrieval
- Ionis neurology pipeline: PrProfile and REVEAL ↗Ionis Pharmaceuticals · 2026-08-28
- Official issuer and R&D disclosure · Ionis Pharmaceuticals, Inc. ↗Ionis Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · Ionis Pharmaceuticals, Inc. ↗Ionis Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · Ionis Pharmaceuticals, Inc. ↗Ionis Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · Ionis Pharmaceuticals, Inc. ↗Ionis Pharmaceuticals, Inc. ·
- Ionis investor FAQs ↗Ionis Pharmaceuticals · Accessed 2026-11-04; undated unless stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.